Related Experiment Video

Updated: Aug 21, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia

Donald J Jurgens, Alvaro Moreno-Aspitia, Ayalew Tefferi

    Haematologica
    |November 9, 2004
    PubMed

    Insights

    Idiopathic cardiomyopathy was diagnosed in 11 patients with polycythemia vera or essential thrombocythemia. Anagrelide use preceded cardiomyopathy in 6 patients, who improved after stopping the medication.

    Area of Science:

    • Cardiology
    • Hematology
    • Pharmacology

    Background:

    • Idiopathic cardiomyopathy is a significant cardiac condition.
    • Polycythemia vera and essential thrombocythemia are myeloproliferative neoplasms.

    Observation:

    • A retrospective review identified 11 patients with idiopathic cardiomyopathy following diagnoses of polycythemia vera or essential thrombocythemia.
    • Echocardiograms confirmed cardiomyopathy in all identified cases.

    Findings:

    • Anagrelide therapy was identified as a potential factor in 6 of the 11 patients.
    • Discontinuation of anagrelide led to symptomatic and/or objective improvement in all 6 patients.
    • This suggests a temporal association between anagrelide use and the development of cardiomyopathy.

    Implications:

    • Anagrelide may be associated with the development of idiopathic cardiomyopathy in patients with myeloproliferative neoplasms.
    • Further research is warranted to elucidate the potential cardiotoxic effects of anagrelide.
    • Clinicians should consider monitoring cardiac function in patients on anagrelide therapy, particularly those with pre-existing hematologic conditions.

    Related Concept Videos

    Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

    Cardiomyopathy III: Hypertrophic Cardiomyopathy

    Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
    Cardiomyopathy II: Dilated Cardiomyopathy01:30

    Cardiomyopathy II: Dilated Cardiomyopathy

    Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
    Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

    Cardiomyopathy IV: Restrictive Cardiomyopathy

    Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
    Myocarditis III: Medical Management01:14

    Myocarditis III: Medical Management

    Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
    Rheumatic Heart Disease I: Introduction01:23

    Rheumatic Heart Disease I: Introduction

    Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

    Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
    Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...